Table I.
Characteristics of Elderly PCNSL Patients who Received Low-Dose Lenalidomide Maintenance After Methotrexate-Based Induction Therapy.
| Pt | Age (years)/ Sex |
Disease site | KPS at Dx |
IELSG score |
Medical comorbidities |
Induction therapy |
Median MTX dose (range) g/m2 |
Interval between diagnosis and lenalidomide (months) |
Lenalidomide dose |
Duration of maintenance lenalidomide (months) |
PFS (months) |
OS (months) |
Disease status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72/M | Cerebellum, IOL | 60 | 4 | CAD, HLD, DM2 | MT-R | 6 (6-8) | 19.6 | 5 mg/day | 65.2 | 84.8 | 89.8+ | CR2 |
| 2 | 78/M | Multifocal, IOL | 60 | 4 | HepB, HTN, DM2, Macular Degeneration | M-R | 3 | 3.4 | 5 mg/day | 40.4 | 43.8 | 84.2+ | CR2 |
| 3 | 75/M | Periventricular | 60 | 4 | HTN | MT-R | 5 (5-5.5) | 5.2 | 5 mg/day | 0.9 | 59.2 | 59.2 | CR1* |
| 4 | 86/F | Temporal lobe | 60 | 4 | HTN, HLD, Oral Cancer | MT-R | 2.5 (2.5-3.5) | 9.2 | 5/10 mg QOD | 38.8 | 48.0 | 57.9+ | PD |
| 5 | 86/M | Frontal lobe, IOL | 60 | 3 | GERD, HLD | 3 Fx WBRT → MT-R | 2 (1-2) | 6.0 | 5 mg/day | 21.0 | 29.4 | 40.0+ | CR2 |
| 6 | 75/M | Periventricular | 80 | 3 | PMR, CAD, HTN, GERD | MT-R | 8 (4-8) | 9.7 | 5 mg/day | 3.8 | 38.0+ | 38.0+ | CR1 |
| 7 | 77/F | Multifocal, deep | 60 | 4 | None | MT-R | 2 (1-4) | 8.3 | 5 mg/day | 23.3+ | 31.6+ | 31.6+ | CR1 |
| 8 | 70/F | Periventricular | 70 | 3 | Hypothyroidism | MT-R | 4.8 (4.4-6) | 7.7 | 5 mg/day | 19.4+ | 27.1+ | 27.1+ | CR1 |
| 9 | 77/M | Periventricular, deep | 70 | 4 | CAD | M-R | 2.5 (2-2.5) | 5.7 | 10 mg/day | 14.5+ | 20.2+ | 20.2+ | CR1 |
| 10 | 83/F | Multifocal, deep | 60 | 4 | HTN, DM2, Hypothyroidism, Stage 3 CKD | MT-R | 0.75 (0.5-1) | 4.6 | 5 mg/day | 17.5+ | 22.1+ | 22.1+ | CR1 |
| 11 | 75/F | Multifocal, deep | 50 | 5 | Stage 3 CKD | MT-R | 1 (0.5-1) | 9.0 | 5 mg/day | 8.4 | 27.2 | 27.7+ | PD |
| 12 | 85/F | Suprasellar, deep | 60 | 5 | HTN, Hypothyroidism, DM2, Stage 3 CKD | MT-R | 2.5 | 5.6 | 5 mg/day | 6.6+ | 12.2+ | 12.2+ | CR1 |
| 13 | 78/F | Multifocal, deep | 50 | 4 | HTN, Hypothyroidism, DM2 | MT-R | 1.5 (1.5-4) | 4.0 | 5 mg/day | 4.1+ | 8.1+ | 8.1+ | CR1 |
: deceased.
CAD: coronary artery disease; CKD: chronic kidney disease; CR1: first complete remission; CR2: second complete remission; DMII: type II diabetes mellitus; Dx: diagnosis; F: female; GERD: gastroesophageal reflux disease; HepB: hepatitis B; HLD: hyperlipidaemia; HTN: hypertension; IELSG: International Extranodal Lymphoma Study Group; IOL: intraocular lymphoma; KPS: Karnofsky performance status; M: male; MT-R: methotrexate, temozolomide, rituximab; MTX: methotrexate; OS: overall survival; PCNSL: primary central nervous system lymphoma; PD: progressive disease; PFS: progression-free survival; PMR: polymyalgia rheumatica; QOD: every other day; WBRT: whole brain irradiation.